Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Expression of AXL earmarks melanoma cells resistant to BRAF and MEK inhibitors that either pre-exist in treatment-naive tumors or emerge in response to therapy. The combination of an AXL-MMAE antibody-drug conjugate with BRAF and MEK inhibitors eliminates heterogeneous melanoma cell populations and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2018-02, Vol.24 (2), p.203-212
Hauptverfasser:	Boshuizen, Julia, Koopman, Louise A, Krijgsman, Oscar, Shahrabi, Aida, van den Heuvel, Elke Gresnigt–, Ligtenberg, Maarten A, Vredevoogd, David W, Kemper, Kristel, Kuilman, Thomas, Song, Ji-Ying, Pencheva, Nora, Mortensen, Jens Thing, Foppen, Marnix Geukes, Rozeman, Elisa A, Blank, Christian U, Janmaat, Maarten L, Satijn, David, Breij, Esther C W, Peeper, Daniel S, Parren, Paul W H I
Format:	Artikel
Sprache:	eng
Schlagworte:	101/1 13/1 13/106 13/109 13/31 13/51 14/1 14/105 14/19 38/35 38/39 631/67/1059/2326 631/67/2329 64/60 82/1 82/51 Antibodies Anticancer properties Antitumor agents Axl protein Biomedicine Biopharmaceuticals Cancer Cancer Research Cervical cancer Cervix Combinatorial analysis Complications and side effects Dosage and administration Drug resistance Drug therapy Genetic aspects Health aspects Heterogeneity Infectious Diseases Inhibitor drugs Inhibitors Lethality Lung cancer MAP kinase MEK inhibitors Melanoma Metabolic Diseases Molecular Medicine Monoclonal antibodies Neurosciences Pancreas Pancreatic cancer Populations Protein-tyrosine kinase receptors Therapy Transcription Tumors Tyrosine Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!